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ABSTRACT 
Background: Hepatitis C Virus (HCV) is an agent of Transfusion Transmissible Infection (TTI) which 
serves as a threat to blood safety and sufficiency of blood and blood products supply.  
Objectives: This study aimed at determining the distribution patterns of HCV among potential blood donors 
in a private Blood Bank in Osogbo, Nigeria.  
Materials and Methods: Over a period of 6 months, 290 consenting prospective blood donors were 
recruited for this study by convenient sampling technique. Pre-test counseling was done, before blood 
specimen collection and laboratory serological analysis was carried out, using third generation Enzyme 
Immunoassay Technique.  
Results: The mean age of the respondents was 35.99 ±10.94 years. A total of 6 participants (2.07%) tested 
positive for anti-HCV. In this study, HCV prevalence has no association with age and blood type, but it does 
with the donor type, where the prevalence is higher among commercial blood donors.  
Conclusion: The rates were lower than the previous studies in Nigeria perhaps this is due to the positive 
effect of public awareness on transfusion transmissible infections and the fact that majority of the donors 
were regular donors. Blood transfusion services should be further strengthened by establishment of blood 
transfusion committees at State level, to regulate and monitor the practice, especially in the private sector, 
with a view to ensure that stringent criteria are adhered to in blood donors’ selection. 
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lood transfusion is an essential part of 
patients' care. Transfusion of blood 
components plays a fundamental role in 
the management of various pathologies and is 
sometimes a life-saving treatment. 
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Blood is a limited resource whose financial 
worth is unquantifiable. Albeit, sale of blood 
and other body tissues is prohibited by 
ethics1, recompense and transaction in blood 
transfusion services cannot be totally 
avoided2, 3. Over the last 20 years, there has 
been a progressive increase in demands for 
blood products, mainly as a result of the 
advances in oncohaematological therapies and 
the increase in major surgery4. Thus, this 
translates into increased risk proportional to 
increase in volume of transfusion practices5. 
Transfusion-transmissible infections (TTIs) 
are infections transmissible from person-to-
person through administration of blood or 
blood products 6.Known agents of  some TTIs 
include: Hepatitis A virus (HAV), Hepatitis B 
virus (HBV), Hepatitis C virus (HCV), 
Hepatitis D virus (HDV), hepatitis G virus 
(HGV),Human Immunodeficiency Virus 
(HIV), Treponemapallidum, Plasmodium 
B 
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species and Human T-lymphotropicViruses-1 
and II (HTLV-1 and II)7, 8. 
Available data indicate that approximately 
3% of the world’s population is infected with 
HCV9.  
In Nigeria, Egah et al.10 reported 6% 
prevalence among the 200 blood donors 
studied in Jos. This is also similar to the 5.8% 
prevalence reported among blood donors 
from southern Nigeria11. The prevalence rates 
found by these authors are however higher 
than the 2.8% found among blood donors in 
Ghana 12 and the 2.9% found among blood 
donors in Port Harcourt13; but lower than the 
12.3% prevalence reported among Nigerian 
blood donors in Benin city14 and the 15.8% 
recorded among Egyptian blood donors15. 
In developing nations, blood safety continues 
to be a major dilemma due to high prevalence 
of infectious agents among blood donors 
compounded with the problem of limited 
resources that preclude the use of 
sophisticated, sensitive and specific 
technologies for screening blood and blood 
products. The economic costs of a failure to 
control transmission of infections includes 
increased requirements for medical care, 
higher levels of dependency and the loss of 
productive labour force which places heavy 
burdens on already overstretched health and 
social services and on the national economy16. 
The literature revealed that the prevalence of 
HCV among blood donors varies from one 
population to another and constitute a major 
source of concern in blood safety globally but 
particularly in developing countries, including 
Nigeria15. Private blood banks constitute 
about 50% of blood transfusion sources in 
Osun State and the only source to access this 
component of healthcare during industrial 
strike periods of government employees-
situation that is now common in Nigeria17. 
This study aimed at determining the 
distribution pattern of Hepatitis C Virus 
(HCV) infection among prospective blood 
donors in a private diagnostic center in 
Osogbo, the capital city of the State of 
Osun.The objectives, therefore, included: to 
determine the prevalence of anti-HCV among 
blood donors in the private sector of blood 
transfusion service of Osogbo, Nigeria and 
provide relevant information to authorities 
that can assist in assessing the need for local 
legislations by states’ houses of assembly and 
policies on safe blood transfusion. Outcome 
of this work will be useful as a source of 
reference and knowledge to readers while also 
serving as a gate opener for further 
researches. 
MATERIALS AND METHODS: 
Study setting: 
This study was carried out in Group 
Diagnostica Laboratory- a major private 
medical laboratory in Osogbo, the capital city 
of Osun State; in the southwest geopolitical 
zones of Nigeria.  The laboratory operates a 
Blood Bank where blood donation exercises 
and blood units and products storage are 
being rendered as services.  
Study subjects: 
A total of two hundred and ninety (290) 
prospective apparently healthy blood donors 
who presented themselves for pre-donation 
screening exercise at Group Diagnostica, 
Osogbo between April and September, 2013 
were recruited for this study. All the blood 
donors were offered pre-test and post-test 
counseling. The participants ages were 
between 18 and 65 years, with a body weight 
of 50kg and above for male and 45kg and 
above for female. The 3 predominant types of 
donors being customarily accepted for 
donation in Nigerian communities were 
included as they approach the laboratory, 
sequentially. These include: voluntary donors, 
relative donors and paid donors.  
Care was taken to ensure that no donor is 
used more than once and those who have 
history of recent ill health, received blood 
transfusion or who had donated blood within 
the last 3 months prior to this study were 
excluded. Individuals with packed cell 
volume (PCV) values less than 35% and 32% 
for male and female respectively, history of 
jaundice, sickle cell disease, hypertension and 
history of current fever were also excluded.  
Procedure: 
Five milliliters (5ml) of venous blood were 
collected from each subject by venepuncture 
into vacuum EDTA tube. The specimens were 
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centrifuged at 1200 revolution per minute 
(rpm) for 5 minutes to harvest plasma into a 
microtube for the anti-HCV (IgG) testing with 
third generation Enzyme Immuno-Assay 
(EIA) method. Donor’s plasma was added to 
the microwell together with a second antibody 
conjugated with the enzyme horseradish 
peroxidase (the HRP-Conjugate) and directed 
against different epitopes of HCV. During 
incubation, the specific immunocomplex 
formed in case of presence of anti-HCV in the 
sample, was captured on the solid phase 
which generates an optical signal that is 
proportional to the amount of anti-HCV 
antibodies present in the sample. The 
commercially prepared positive and negative 
controls were treated alongside the 
specimens. A cut-off value was determined 
and results were interpreted as positive and 
negative according to manufacturer’s 
instructions18. 
Statistical analysis:  
The data generated were coded, entered, 
validated and analyzed using Statistical 
Package for Social Science (SPSS) version 
17.0. The seroprevalence of HCV were 
expressed for the entire study group and 
comparison of means and variances were 
done by age, sex, blood group, blood donor 
type using t- test and levene’s test 
respectively. Values below 0.05 were 
considered significant. The prevalence was 
also illustrated in pie charts. 
RESULTS: 
A total of two hundred and ninety (290) 
apparently healthy prospective blood donors 
aged between 18 and 65 years (Mean±SD, 
35.99±10.94 years) who presented themselves 
for blood donation at Group Diagnostica, 
Osogbo were studied.  Of the 290 blood 
donors, 283 (97.6%) were males. Also, 185 
(63.8%) of the participants belong to the most 
active age group of 28-47. Of the 290 
asymptomatic subjects, 217(74.8%) belong to 
O Rh D positive blood types, while there is 
neither AB Rh D positive nor B Rh D 
negative individuals included. Majority 
(91.7%) of the participants was paid donors 
while relative and voluntary donors 
constituted 7.2% and 1%, respectively. Six 
(6) of the prospective blood donors 
representing 2.07% had serological evidence 
of infection with HCV. When subjected to 
statistical analysis using SPSS version 17,  the 
Levene’s test for equality of variance and t 
test for equality of means reveal no 
significant differences on prevalence on 
account of age (P=0.440) and blood group 
(P=0.755). However the donor’s type shows 
significant difference (P=0.0000) with 
commercial donors being most vulnerable. 
Socio-demographical characteristics of the 
study group are shown in Table (1). Figure 
(1) shows the prevalence of anti-HCV among 
the subjects. 
Table (1): Social-demographic data of studied 
participants 
Characteristics Frequency         % 
Age (Year)   
   18-27 61 21.0 
   28-37 119 41.0 
   38-47 66 22.8 
   48-57 29 10.0 
   58-67 15 5.2 
Gender   
   Male 283 97.6 
   Female 7 2.4 
Type of donor   
   Paid 266 91.7 
   Relative 21 7.2 
  Voluntary 3 1.0 
Blood Group   
   O Positive 217 74.8 
   O Negative 16 5.5 
   A Positive 30 10.3 
   B Positive 23 7.9 
   A Negative 2 0.7 
   AB Negative 2 0.7 
DISCUSSION: 
Hepatitis C Virus has emerged as the 
commonest cause of post-transfusion 
hepatitis. With no vaccine on site and low 
success rate of therapy, HCV has remained a 
major source of concern in Blood Safety 
globally. The male: female ratio of donors in 
this study was found to be 40.43:1. There was 
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a preponderance of male donors. This is 
probably due to an apathy associated with 
female donors as a result of physiological 
conditions like pregnancy, menstruation and 
lactation which make them unsuitable to 
donate blood during these periods.  
This study shows prevalence of HCV to be 
2.07% in the cosmopolitan city of Osogbo. 
This finding partly agree with 1.8% reported 
in Kaduna 19  but is lower than 5.8% and  6% 
reported in southern Nigeria and Osogbo, 
respectively20, 21. It is also somewhat lower 
than the 2.8% found among blood donors in 
Ghana 12 and the 2.9% found among blood 
donors in Port Harcourt 13. The  
seroprevalence rate found in this study is 
however higher than values ranging between 
0 and 1.4% reported from USA and Europe 21-
23. 
 
Figure (1): Prevalence of anti-HCV among 
the studied donors. 
The differences in prevalence rates of anti-
HCV between developed countries where 
rates are low and developing countries where 
prevalence rates are higher may be explained 
by certain factors. These include socio-
cultural practices involving the use of 
instruments contaminated by blood and body 
fluids for procedures such as scarification, 
tattooing, circumcision which are common 
practices in many developing countries.  
The finding of a high prevalence of anti-HCV 
antibodies among apparently healthy blood 
donors in Osogbo further confirms the 
presence of hepatitis C infection in Nigeria 
and brings to the fore the necessity of 
adopting measures that will ensure safe blood 
transfusion.  
Majority of donors tested in this study were 
commercial remunerated donors. The number 
of voluntarily donated blood had continued to 
fall over the years in Nigeria due to logistics 
or organizational problems associated with 
the Nigeria Blood Transfusion service that is 
supposed to provide voluntarily donated 
blood given out of altruism.  The net result is 
that commercial blood donation is the order 
of the day. This observation is consistent with 
the findings elsewhere and the suggestion by 
the World Health Organization (WHO) that 
commercial remunerated blood donors and 
family replacement donors are more likely to 
transmit transfusion-transmissible infections 
(TTI’s) than voluntary donors16. The low 
number of voluntary non-remunerated donors 
may be attributed to several factors- inability 
to retain first-time voluntary donors, lack of 
enlightenment of the populace, socio-cultural 
and religious factors, lack of motivation, 
logistics problems and poor economic status 
of the masses. Indeed, there is general apathy 
surrounding voluntary blood donation. This 
scenario constitutes a high risk for patients 
who are in need of blood. 
CONCLUSION: 
The prevalence of HCV in the private blood 
banking sector in Osogbo, Southwest Nigeria 
is 2.07%. There was no relationship between 
blood groups, age and gender; and infection 
with HCV in the study. 
Based on our findings, it is recommended, 
therefore that: screening of prospective blood 
donors for HCV as a transfusion transmissible 
infection should be made mandatory in all  
private and public blood banks alike while 
efforts should be geared towards evolving a 
sustainable register of voluntary, non-
remunerated donors for the nation through 
strengthening of National Blood Transfusion 
Services (NBTS).Periodic study to investigate 
transfusion transmissible infections is 
required to enable safety reviews of the blood 
supply. There is urgent need for renewed 
intensification of preventive programmes 
aimed at high risk behavioral change. 
Finally, establishment of screening centers at 
state level for private operators will help in 
ensuring adherence to stringent screening 
process and ultimately assure safety of blood 
units from HCV and other TTIs. This will 
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legislation at states houses of assembly in 
Nigeria. The ultimate aim of every health care 
system is to provide solution to the overriding 
problem of disease control. 
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